In particular, both nilotinib and imatinib have been shown to prevent TGF-β- and PDGF-induced collagen synthesis in skin fibroblasts, as well as to decrease myofibroblast formation in experimental scleroderma [43,117,122]. This evidence concerns the gene TGFB1 and scleroderma.